Objective: To 1) compare monthly serum levels of matrix metalloproteinase-g
(MMP-9) and tissue inhibitor of MMP-type 1 (TIMP-1) in patients with relap
sing-remitting MS (RRMS) versus healthy controls and 2) determine the relat
ionship among monthly serum levels of MMP-9 and TIMP-1 and MRI activity. Ba
ckground: Activated T-cells and macrophages secrete MMPs that may facilitat
e their migration across vascular subendothelial basement membranes into th
e CNS. The serum concentration of MMP-9 is reported to be higher in patient
s with RRMS than healthy controls. Methods: Monthly evaluations including g
adolinium-enhanced (Gd+) brain MRI and measures of serum MMP-9 and TIMP-1 w
ere performed for up to 15 months in 24 patients with RRMS and for up to 4
months in 10 controls. Results: Serum MMP-9 but not TIMP-1 levels are eleva
ted in RRMS patients compared to healthy controls (p = 0.025, p = 0.61). In
a univariate analysis, high MMP-9 and low TIMP-1 levels precede appearance
of new Gd+ lesions (respectively; odds ratio = 3.3, p = 0.008; odds ratio
= 2.2, p = 0.086). In a multivariate analysis, in comparison to months when
MMP-9 is low and TIMP-1 high, MRI scans obtained the month following high
MMP-9 and low TIMP-1 serum concentrations are more likely to report new Gd lesions (p = 0.0006, odds ratio = 21.5). Conclusion: An increase in the ac
tivity of matrix metalloproteinase-9 (MMP-9) relative to tissue inhibitor o
f MMP-type 1 (TIMP-1) may be related to formation of new MS lesions, sugges
ting that serum levels of MMP-9 and TIMP-1 may be surrogate markers of dise
ase activity in relapsing-remitting MS.